|Mr. Alfred F. Altomari||Chairman, Pres & CEO||971.11k||N/A||1959|
|Mr. Geoffrey P. Gilmore||Sr. VP, Gen. Counsel & Corp. Sec.||592.28k||N/A||1966|
|Mr. Robert G. Conway||Sr. VP & Chief Supply Chain Officer||444.11k||N/A||1957|
|Mr. Dennis P. Reilly||Sr. VP & CFO||N/A||N/A||1959|
|Ms. Tristen Herrstrom||Sr. VP of HR & Admin.||N/A||N/A||N/A|
|Matthew Riley||Head of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Amy Welsh||VP of Marketing||N/A||N/A||N/A|
|Ms. Kimberly Whelan||VP of Sales & Market Access||N/A||N/A||N/A|
|Dr. Elizabeth Ijeoma Onyemelukwe Garner||Consultant||N/A||N/A||1968|
|Dr. Paul Korner||Chief Medical Officer||N/A||N/A||1966|
Agile Therapeutics, Inc., a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
Agile Therapeutics, Inc.’s ISS Governance QualityScore as of November 2, 2019 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 8; Compensation: 6.